Aequus Pharmaceuticals (CVE:AQS) Hits New 52-Week Low – Here’s What Happened

Aequus Pharmaceuticals Inc. (CVE:AQS)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 26059 shares changing hands. The stock had previously closed at C$0.01.

Aequus Pharmaceuticals Price Performance

The company’s 50-day simple moving average is C$0.01 and its 200-day simple moving average is C$0.01. The company has a debt-to-equity ratio of 138.88, a current ratio of 0.07 and a quick ratio of 0.46. The stock has a market capitalization of C$1.33 million, a price-to-earnings ratio of -1.00 and a beta of -0.02.

Aequus Pharmaceuticals Company Profile

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.